Drug profile · INN
dostarlimab-gxly
JEMPERLI
dostarlimab-gxly (JEMPERLI) is a programmed cell death protein 1 antagonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — dostarlimab-gxly
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 15
- Programs
- 1
- Data quality
- 0.84
Quick answer
dostarlimab-gxly (JEMPERLI) is a programmed cell death protein 1 antagonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Programmed cell death protein 1 antagonist
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12343342
Methods for treating soft tissue sarcoma
granted -
US 11866444
Oxabicycloheptane prodrugs
granted -
US 11236102
Oxabicycloheptane prodrugs
granted -
US 10618908
Oxabicycloheptane prodrugs
granted -
US 10399993
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
granted -
US 10364252
Oxabicycloheptane prodrugs
granted -
US 10023587
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
granted -
US 9994584
Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
granted -
US 9988394
Oxabicycloheptane prodrugs
granted -
US 9079917
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
granted -
US 8822461
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
granted -
US 8541458
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
granted -
US 8426444
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
granted -
US 8227473
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
granted -
US 7998957
Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use
granted
Frequently asked questions
What is dostarlimab-gxly?
dostarlimab-gxly (JEMPERLI) is a programmed cell death protein 1 antagonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dostarlimab-gxly?
JEMPERLI is a marketed brand name for dostarlimab-gxly. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dostarlimab-gxly?
dostarlimab-gxly has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.